Glioma immunology and immunotherapy

Neurosurgery

Volumn 46, Issue 4, 2000, Pages 778-792

  Parney, Ian F ^a   Hao, Chunhai ^a   Petruk, Kenneth C ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cytokine; Gene therapy; Glioma; Immunology; Immunotherapy

Indexed keywords

ANTIBODY; CYTOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; TUMOR ANTIGEN; VACCINE;

ADOPTIVE TRANSFER; CLINICAL TRIAL; DENDRITIC CELL; GENE THERAPY; GLIOMA; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOBIOLOGY; IMMUNOSTIMULATION; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0034118217     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/00006123-200004000-00002     Document Type: Review

References (190)

1. Ahmed R, Grah D: Immunological memory and protective immunity: Understanding their relation. Science 272:54-60, 1996.
2. Ashley DM, Kong FM, Bigner DD, Hale LP: Endogenous expression of transforming growth factor beta 1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model. Cancer Res 58:302-309, 1998.
3. Ashley DM, Sampson JH, Archer GE, Batra SK, Bigner DD, Hale LP: A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo. J Neuroimmunol 78:34-46, 1997.
4. Atkinson EA, Bleackley RC: Mechanisms of lysis by cytotoxic T cells. Crit Rev Immunol 15:359-384, 1995.
5. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH: Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70:175-182, 1989.
6. Batra SK, Niswonger ML, Wikstrand CJ, Pegram CN, Zalutsky MR, Morrison SL, Bigner DD: Mouse/human chimeric Mel-14 antibody: Genomic cloning of the variable region genes, linkage to human constant region genes, expression, and characterization. Hybridoma 13:87-97, 1994.
7. Bennett SRM, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR: Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478-480, 1998.
8. Berns A, Clift S, Cohen L, Donehower R, Dranoff G, Hauda K, Jaffee E, Lazenby A, Levitsky H, Marshall F: Clinical protocol: Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum Gene Ther 6:347-368, 1995.
9. Bertrand I, Mannen H: Etude des réactions vasculaires dans les astrocytomes. Rev Neurol (Paris) 102:3-19, 1960.
10. 131-radiolabeled monoclonal antibodies antitenascin 81C6 and anti-chondroitin proteoglycan sulfate Mel-14 F (ab′)2: A preliminary report. J Neurooncol 24:109-122, 1995.
11. Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ, Herndon JE, Vick NA, Paleologos N, Cokgor I, Provenzale JM, Zalutsky MR: Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results. J Clin Oncol 16: 2202-2212, 1998.
12. Black KL, Chen K, Becker DP, Merrill JE: Inflammatory leukocytes associated with increase immunosuppression by glioblastoma. J Neurosurg 77:120-126, 1992.
13. Bloom HJ, Peckham MJ, Richardson AE, Alexander PA, Payne PM: Glioblastoma multiforme: A controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy. Br J Cancer 27:253-267, 1973.
14. Bodmer S, Strommer K, Frei K: Immunosuppression and transforming growth factor beta in glioblastoma: Preferential production of transforming growth factor beta 2. J Immunol 143:3222-3229, 1989.
15. Boethius J, Blomgren H, Collins VP, Greitz T, Strander H: The effect of systemic human interferon-alpha administration to patients with glioblastoma multiforme. Acta Neurochir (Wien) 68:239-251, 1983.
16. Bourdon MA, Coleman RE, Blasberg RG, Groothuis DR, Bigner DD: Monoclonal antibody localization in subcutaneous and intracranial human xenografts: Paired label and imaging analysis. Anticancer Res 4:133-140, 1984.
17. Bourdon MA, Wikstrand CJ, Furthmayr H, Matthews TJ, Bigner DD: Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res 43:2796-2805, 1983.
18. Brooks WH, Markesbery WR, Gupta GD, Roszman TL: Relationship of lymphocytic invasion and survival in brain tumor patients. Ann Neurol 4:219-224, 1978.
19. Brooks WH, Netsky MG, Normansell DE, Horwitz DA: Depressed cell-mediated immunity in patients with primary intracranial tumors. J Exp Med 136:1621-1647, 1972.
20. Bullard DE, Schold SC, Bigner SH, Bigner DD: Growth and chemotherapeutic responsiveness in athymic mice of tumors arising from human glioma-derived cell lines. J Neuropathol Exp Neurol 40:410-427, 1981.
21. Bundy GM, Merchant RE: Basic research applied to neurosurgery: Lymphocyte trafficking to the central nervous system. Neurosurg Q 6:51-68, 1996.
22. Chi DDJ, Merchant RE, Rand R, Conrad AJ, Garrison D, Turner R, Morton DL, Hoon DS: Molecular detection of tumorassociated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 150:2143-2152, 1997.
23. Colapinto EV, Humphrey PA, Zalutsky MR, Groothuis DR, Friedman HS, de Tribolet N, Carrel S, Bigner DD: Comparative localization of murine monoclonal antibody Mel-14 F(ab′)2 fragment and whole IgG2a in human glioma xenografts. Cancer Res 48:5701-5707, 1988.
24. Cserr HF, Knopf PM: Cervical lymphatics, the blood-brain barrier, and the immunoreactivity of the brain: A new view. Immunol Today 13:507-512, 1992.
25. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Haurada H, Pardoll D, Mulligan R: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90:3539-3543, 1993.
26. Ellem KAO, O'Rourke MG, Johnson GR, Parry G, Misko IS, Schmidt CW, Parsons PG, Burrows SR, Cross S, Fell A, Li CL, Bell JR, Dubois PJ, Moss DJ, Good MF, Kelso A, Cohen LK, Dranoff G, Mulligan RC: A case report: Immune responses and clinical course of the first human use of granulocyte/ macrophage-colony-stimulating factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol Immunother 44:10-20, 1997.
27. Elliott L, Brooks WH, Roszman T: Role of interleukin-2 and interleukin-2 receptor in the proliferative defect observed in mitogen-stimulated lymphocytes from patients with gliomas. J Natl Cancer Inst 78:919-922, 1987.
28. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE: Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci U S A 93:2909-2914, 1996.
29. Farkkila M, Jääskeläinen J, Kallio M, Blomstedt G, Raininko R, Virkkunen P, Paetau A, Sarelin H, Mantyla M: Randomized, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma. Br J Cancer 70:138-141, 1994.
30. Fathallah-Shaykh HM, Gao W, Cho M, Herrera MA: Priming in the brain, an immunologically privileged organ, elicits antitumor immunity. Int J Cancer 75:266-276, 1998.
31. Federoff S, Hao C: Origin of microglia and their regulation by astroglia. Adv Exp Med Biol 296:135-142, 1991.
32. Ferrone S, Marincola FM: Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance, and clinical relevance. Immunol Today 16:487-494, 1995.
33. Fine HA: Biologic-based approaches toward the therapy of malignant gliomas, in Black PM, Loeffler JS (eds): Cancer of the Nervous System. Cambridge, Blackwell Science, 1997, pp 213-226.
34. Fontana A, Constam DB, Frei K, Malipiero U, Pfister HW: Modulation of the immune response by transforming growth factor beta. Int Arch Allergy Immunol 99:1-7, 1992.
35. Fontana A, Kristensen F, Dubs R, Gemsa D, Weber E: Production of prostaglandin E and interleukin-1 like factor by cultured astrocytes and C6 glioma cells. J Immunol 129:2413-2419, 1982.
36. Fuchs EJ, Matzinger P: B cells turn off virgin but not memory T cells. Science 258:1156-1159, 1992.
37. Gehrmann J, Matsumoto Y, Kreutzberg GW: Microglia: Intrinsic immunoeffector cell of the brain. Brain Res Rev 20:269-287, 1995.
38. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM: Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci U S A 90:6586-6590, 1993.
39. Glick RP, Lichtor T, Kim TS, Ilangovan S, Cohen EP: Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo. Neurosurgery 36:548-555, 1995.
40. Glick RP, Lichtor T, Mogharbel A, Taylor CA, Cohen EP: Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma. Neurosurgery 41:898-907, 1997.
41. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee EM, Karasuyama H, Baker M, Pardoll DM: Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254: 713-716, 1991.
42. Grabbe S, Beissert S, Schwarz T, Granstein RD: Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy? Immunol Today 16:117-121, 1995.
43. Gratas C, Tohma Y, Van Meir EG, Klein M, Tenan M, Ishii N, Tachibana O, Kleihues P, Ohgaki H: Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol 7:863-869, 1997.
44. Greene HSN: The transplantation of tumours to the brains of heterologous species. Cancer Res 11:529-534, 1951.
45. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189-1192, 1995.
46. Griffitt W, Glick RP, Lichtor T, Cohen EP: Survival and toxicity of an allogeneic cytokine-secreting fibroblast vaccine in the central nervous system. Neurosurgery 42:335-340, 1998.
47. Grimm EA, Bruner JM, Carinhas J, Koppen JA, Loudon WG, Owen-Schaub L, Steck PA, Moser RP: Characterization of interleukin-2-initiated versus OKT3-initiated human tumor-infiltrating lymphocytes from glioblastoma multiforme. Cancer Immunol Immunother 32:391-399, 1991.
48. Grimm EA, Mazumbder A, Zhang HZ: Lymphokine activated killer cell phenomenon: Lysis of natural killer resistant fresh solid tumor cells by interleukin-2 activated autologous peripheral blood lymphocytes. J Exp Med 155:1823-1841, 1982.
49. Hao C, Richardson A, Federoff S: Macrophage-like cells originate from neuroepithelium in culture: Characterization and properties of the macrophage-like cells. Int J Dev Neurosci 9:1-14, 1991.
50. Herrlinger U, Kramm CM, Johnston KM, Louis DN, Finkelstein D, Reznikoff G, Dranoff G, Breakefield XO, Yu JS: Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther 4:345-352, 1997.
51. Hodge J, Abrams S, Schlom J, Kantor J: Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 54:5552-5555, 1994.
52. Holladay FP, Heitz T, Chen YL, Chiga M, Wood GW: Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes. Neurosurgery 31:528-533, 1992.
53. Holladay FP, Heitz T, Wood GW: Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells. J Neurosurg 77:757-762, 1992.
54. Holladay FP, Heitz-Turner T, Bayer WL, Wood GW: Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma. J Neurooncol 27:179-189, 1996.
55. Holladay FP, Lopez G, De M, Morantz RA, Wood GW: Generation of cytotoxic immune responses against a rat glioma by in vivo priming and secondary in vitro stimulation with tumor cells. Neurosurgery 30:499-505, 1992.
56. Hong L, Johannsen L, Krueger JM: Modulation of human leukocyte antigen DR expression in glioblastoma cells by interferon gamma and other cytokines. J Neuroimmunol 35:139-152, 1991.
57. Huettner C, Czub S, Kerkau S, Roggendorf W, Tonn JC: Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res 17:3217-3224, 1997.
58. Huettner C, Paulus W, Roggendorf W: Messenger RNA: Expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol 146:317-322, 1995.
59. Iwasaki K, Rogers LR, Estes ML, Barna BP: Modulation of proliferation and antigen expression of a cloned human glioblastoma by interleukin-4 alone and in combination with tumor necrosis factor-alpha and/or interferon-gamma. Neurosurgery 33:489-494, 1993.
60. Jääskeläinen J, Kalliomaki P, Paetau A, Timonen T: Effect of LAK cells against three-dimensional tumor tissue: In vitro study using multi-cellular human glioma spheroids as targets. J Immunol 142:1036-1045, 1989.
61. Jääskeläinen J, Maenpaa A, Patarroyo M, Gahmberg CG, Somersalo K, Tarkkanen J, Kallio M, Timonen T: Migration of recombinant IL-2-activated T and natural killer cells in the intercellular space of human H-2 glioma spheroids in vitro. J Immunol 149:260-268, 1992.
62. Jachimczak P, Schwulera U, Bogdahn U: In vitro studies of cytokine-mediated interactions between malignant glioma and autologous peripheral blood mononuclear cells. J Neurosurg 81:579-586, 1994.
63. Jaffee EM, Pardoll DM: Gene therapy: Its potential applications in the treatment of renal-cell carcinoma. Semin Oncol 22:81-91, 1995.
64. Jean WC, Spellman SR, Wallenfriedman MA, Hall WA, Low WC: Interleukin-12-based immunotherapy against rat 9L glioma. Neurosurgery 42:850-857, 1998.
65. Jereb B, Petric-Grabnar G, Klun B, Lamovec J, Skrbec M, Soos E: Addition of IFN-alpha to treatment of malignant brain tumors. Acta Oncol 33:651-654, 1994.
66. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H, Golstein P: Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528-530, 1994.
67. Kasahara T, Mukaida N, Yamashita K, Yagisawa H, Akahoshi T, Matsushima K: IL-1 and TNFa induction of IL-8 and monocyte chemotactic and activating factor (MCAF) mRNA expression in a human astrocytoma cell line. Immunology 74:60-67, 1991.
68. Kondo S, Yin D, Takeuchi J, Morimura T, Miyatake SI, Nakatsu S, Oda Y, Kikuchi H: Tumor necrosis factor-alpha induces an increase in susceptibility of human glioblastoma U87MG cells to natural killer cell-mediated lysis. Br J Cancer 69:627-632, 1994.
69. Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J, Lillehei KO: Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother 45:77-87, 1997.
70. Kruse CA, Kong Q, Schiltz PM, Kleinschmidt-DeMasters BK: Migration of activated lymphocytes when adoptively transferred into cannulated rat brain. J Neuroimmunol 55:11-21, 1994.
71. Kruse CA, Mitchell DH, Kleinschmidt-DeMasters BK, Franklin WA, Morse HG, Spector EB, Lillehei KO: Characterization of a continuous human glioma cell line DBTRG-05MG: Growth kinetics, karyotype, receptor expression, and rumor suppressor gene analyses. In Vitro Cell Dev Biol 28A:609-614, 1992.
72. Kruse CA, Mitchell DH, Lillehei KO, Johnson SD, McCleary EL, Moore GE, Waldrop S, Mierau GW: Interleukin-2-activated lymphocytes from brain tumor patients. Cancer 64:1629-1637, 1989.
73. Kruse CA, Schiltz PM, Bellgrau D, Kong Q, Kleinschmidt-DeMasters BK: Intracranial administrations of single or multiple source allogeneic cytotoxic T lymphocytes: Chronic therapy for primary brain tumors. J Neurooncol 19:161-168, 1994.
74. Krushelnycky BW, Farr-Jones MA, Mielke B, McKean JD, Weir BK, Petruk KC: Development of a large-animal human brain tumor xenograft model in immunosuppressed cats. Cancer Res 51:2430-2437, 1991.
75. Kuppner M, Hamou M, Sawamura Y, Bodmer S, de Tribolet N: Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2. J Neurosurg 71:211-217, 1989.
76. Kurpad SN, Bigner DD: Immunotherapy of malignant gliomas, in Black PM, Loeffler JS (eds): Cancer of the Nervous System. Cambridge, Blackwell Science, 1997, pp 264-287.
77. Kurpad SN, Zhao X-G, Wikstrand CJ, Batra SK, McLendon RE, Bigner DD: Tumor antigens in astrocytic gliomas. Glia 15:244-256, 1995.]
78. Lampson LA: Interpreting MHC class I expression and class I/class II reciprocity in the CNS: Reconciling divergent findings. Microsc Res Tech 32:267-285, 1995.
79. Lampson LA: Immunobiology of brain tumors: Antigens, effectors, and delivery to sites of microscopic tumor in the brain, in Black PM, Loeffler JS (eds): Cancer of the Nervous System. Cambridge, Blackwell Science, 1997, pp 874-906.
80. Lampson LS, Hickey WF: Monoclonal antibody analysis of MHC expression in human brain biopsies: Tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement. J Immunol 136:4054-4062, 1986.
81. Lapena P, Isasi C, Vaquera J, Martinez R, Alvarez-Mon M: Modulation by interferon alpha of the decreased natural killer activity in patients with glioblastoma. Acta Neurochir (Wien) 109:109-113, 1991.
82. Lee YS, Bullard DE, Zalutsky MR, Coleman RE, Wikstrand CJ, Friedman HS, Colapinto EV, Bigner DD: Treatment of intracranial human glioma xenografts with 131-I labeled anti-tanascin monoclonal antibody 81C6. Cancer Res 48:2904-2910, 1988.
83. Leung SY, Wong MP, Chung LP, Chan ASY, Yuen ST: Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathol (Berl) 93:518-527, 1997.
84. Liau LM, Black KL, Prins RM, Sykes SN, DiPatre P-L, Cloughesy TF, Becker DP, Bronstein JM: Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 90:1115-1124, 1999.
85. Lichtor T, Glick RP, Kim TS, Hand R, Cohen EP: Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells. J Neurosurg 83:1038-1044, 1995.
86. Lillehei KO, Mitchell DH, Johnson SD, McCleary EL, Kruse CA: Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 28:16-23, 1991.
87. Lorimer IA, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I: Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci U S A 93:14815-14820, 1996.
88. Lotze MT: Getting to the source: Dendritic cells as therapeutic reagents for the treatment of patients with cancer. Ann Surg 226:1-5, 1997.
89. Mahaley MS, Bigner DD, Dudka LF, Wilds PR, Williams DH, Bouldin TW, Whitaker JN, Bynum JM: Immunobiology of primary intracranial tumors: Part 7 - Active immunization of patients with anaplastic human glioma cells: A pilot study. J Neurosurg 59:201-207, 1983.
90. Mahaley MS, Brooks WH, Rozsman TL, Bigner DD, Dudka L, Richardson S: Immunobiology of primary intracranial tumors: Part I - Studies of the cellular and humoral general immune competence of brain tumor patients. J Neurosurg 46:467-476, 1977.
91. Mahaley MSJ, Gillespie GY, Gillespie RP, Watkins PJ, Bigner DD, Wikstrand CJ, MacQueen JM, Sanfilippo F: Immunobiology of primary intracranial tumors: Part 8 - Serological responses to active immunization of patients with anaplastic gliomas. J Neurosurg 59:208-216, 1983.
92. Mahaley MSJ, Urso MB, Whaley RA, Blue M, Williams TE, Guaspari A, Selker RG: Immunobiology of primary intracranial tumors: Part 10 - Therapeutic efficacy of interferon in the treatment of recurrent gliomas. J Neurosurg 63:719-723, 1985.
93. Mantovani A, Bottazi B, Colotta F, Sozzani S, Ruco L: The origin and function of tumor-associated macrophages. Immunol Today 13:265-270, 1992.
94. Maruno M, Yoshimine T, Nakata H, Nishioka K, Kato A, Hayakawa T: Complete regression of anaplastic astrocytoma by intravenous tumor necrosis factor alpha after recurrence: A case report. Surg Neurol 41:482-485, 1994.
95. Matzinger P: Tolerance, danger, and the extended family. Ann Rev Immunol 12:991-1045, 1994.
96. Matzinger P, Fuchs EJ: Beyond "self" and "non-self": Immunity is a conversation, not a war. J Natl Inst Health Res 8:35-39, 1996.
97. McVicar DW, Davis D, Merchant RE: In vitro analysis of the proliferative potential of T cells from patients with brain tumor: Glioma-associated immunosuppression unrelated to intrinsic cellular defect. J Neurosurg 76:251-260, 1992.
98. Medawar PB: Immunity to homologous grafted skin: III - The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 29:58-69, 1948.
99. Merchant RE, Ellison ED, Young HF: Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. J Neurooncol 8:173-188, 1990.
100. Miescher S, Whiteside TL, de Tribolet N, von Fliedner V: In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers. J Neurosurg 68:438-448, 1988.
101. Miyagi K, Ingram M, Techy GB, Jacques DB, Freshwater DB, Sheldon H: Immunohistochemical detection and correlation between MHC antigen and cell-mediated immune system in recurrent glioma by APAAP method. Neurol Med Chir (Tokyo) 30:649-653, 1990.
102. Miyatake S, Handa H, Yamashita J, Yamasaki T, Ueda M, Namba Y, Hanaoka M: Induction of human glioma-specific cytotoxic T-lymphocyte lines by autologous stimulation and interleukin 2. J Neurooncol 4:55-64, 1986.
103. Morford LA, Elliott LH, Carlson SL, Brooks WH, Roszman TL: T cell receptor-mediated signalling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol 159: 4415-4425, 1997.
104. Morioka T, Baba T, Black KL, Streit WJ: Immunophenotypic analysis of infiltrating leukocytes and microglia in an experimental rat glioma. Acta Neuropathol (Berl) 83:590-597, 1992.
105. Mosmann TR, Sad S: The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17:138-146, 1996.
106. Murphy-Ullrich JE, Lightner VA, Aukhil I, Yan YZ, Erickson HP, Hook M: Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J Cell Biol 115: 1127-1136, 1991.
107. Naganuma H, Sasaki A, Nukui H, Tasaka K: Antiproliferative cytokines secreted by lymphokine-activated killer cells stimulated with tumor cells. J Neurosurg 77:411-416, 1992.
108. Ni K, O'Neill HC: The role of dendritic cells in T cell activation. Immunol Cell Biol 75:223-230, 1997.
109. Nitta T, Hishii M, Sato K, Okamura K: Selective expression of interleukin-10 gene within glioblastoma multiforme. Brain Res 649:122-128, 1994.
110. Ogasawara M, Rosenberg SA: Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes. Cancer Res 53:3561-3568, 1993.
111. Palma L, Di Lorenzo N, Guidetti B: Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas: Incidence, fate, and relevance to prognosis in 228 operated cases. J Neurosurg 49:857-861, 1978.
112. Parney IF, Farr-Jones MA, Chang L-J, Petruk KC: Human glioma immunobiology in vitro: Implications for immunogene therapy. Neurosurgery (in press).
113. Parney IF, Farr-Jones MA, Petruk KC: Improved technique for establishing short term human brain tumor cultures. J Neurooncol 43:1-10, 1999.
114. Parney IF, Petruk KC, Zhang C, Farr-Jones MA, Sykes DB, Chang L-J: GM-CSF and B7-2 combination immunogene therapy in an allogeneic hu-PBL-SCID/beige mouse: Human glioblastoma multiforme model. Hum Gene Ther 8:1073-1085, 1997.
115. Peters JH, Gieseler R, Thiele B, Steinbach F: Dendritic cells: From ontogenetic orphans to myelomonocytic descendants. Immunol Today 17:273-278, 1996.
116. Plautz G, Yang Z, Wu B, Gao X, Huang L, Nabel GJ: Immunotherapy of malignancy by in vivo gene transfer into tumor. Proc Natl Acad Sci U S A 90:4645-1649, 1993.
117. Priestman TJ, Bleehen NM, Rampling R, Stenning S, Nethersell AJ, Scott J: A phase II evaluation of human lymphoblastoid interferon (Wellferon) in relapsed high grade malignant glioma: Medical Research Council Brain Tumour Working Party. Clin Oncol (R Coll Radiol) 5:165-168, 1993.
118. Ramarathinam L, Castle M, Wu Y: T cell costimulation by B7/ BB1 induces CD8 T cell-dependent tumor rejection: An important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med 179:1205-1214, 1994.
119. Rana MW, Pinderton H, Thornton H, Nagy D: Heterotransplantation of human glioblastoma and meningioma to nude mice. Proc Soc Exp Biol Med 155:85-88, 1977.
120. Redd JM, Lagarde AC, Kruse CA, Bellgrau D: Allogeneic tumor-specific cytotoxic T lymphocytes. Cancer Immunol Immunother 34:349-354, 1992.
121. Reder AT, Lascola CD, Flanders SA, Maimone D, Jensen MA, Skias DD, Lancki DW: Astrocyte cytolysis by MHC class II-specific mouse T cell clones. Transplantation 56:393-399, 1993.
122. Reist CJ, Batra SK, Pegram CN, Bigner DD, Zalutsky MR: In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: Comparison with its murine parent. Nucl Med Biol 24:639-647, 1997.
123. Rescigno M, Winzler C, Delia D, Mutini C, Lutz M, Riciardi-Castagnoli P: Dendritic cell maturation is required for initiation of the immune response. J Leukocyte Biol 61:415-121, 1997.
124. Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R, Rubin R: Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce the regression of wild-type tumors. Cancer Res 54:2218-2222, 1994.
125. Restifo NP, Esquivel F, Kawadami Y, Yewdell JW, Mule JJ, Rosenberg SA, Bennink JR: Identification of human cancers deficient in antigen processing. J Exp Med 177:265-272, 1993.
126. Restifo NP, Kawakami Y, Marincola F, Shamamian P, Taggarse A, Esquivel F, Rosenberg SA: Molecular mechanisms used by tumors to escape immune recognition: Immunogenetherapy and the cell biology of major histocompatibility complex class I. J Immunother 14:182-190, 1993.
127. Ridely A, Cavanagh JB: Lymphocytic infiltration in gliomas: Evidence of possible host resistance. Brain 94:117-124, 1971.
128. Ridge JP, Di Rosa F, Matzinger P: A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393:474-478, 1998.
129. Riva P, Franceschi G, Arista A, Frattarelli M, Riva N, Cremonini AM, Giuliani G, Casi M: Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: A six-year clinical experience. Cancer 80:2733-2742, 1997.
130. Roggendorf W, Strupp S, Paulus W: Distribution and characterization of microglia/macrophages in human brain tumors. Acta Neuropathol (Berl) 92:288-293, 1996.
131. Rosenberg SA, Lotze MD, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-acrivated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889-897, 1987.
132. Rossi ML, Hughes JT, Esiri MM, Coakham HB, Brownell DB: Immunohistological study of mononuclear cell infiltrate in malignant gliomas. Acta Neuropathol (Berl) 74:269-277, 1987.
133. Roszman T, Elliott L, Brooks W: Modulation of T-cell function by gliomas. Immunol Today 12:370-374, 1991.
134. Roth W, Fontana A, Trepel M, Reed JC, Dichgans J, Weller M: Immunochemotherapy of malignant glioma: Synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunol Immunother 44:55-63, 1997.
135. 2+-independent T cell mediated cytotoxicity. J Exp Med 177:195-200, 1993.
136. Saito T, Tanaka R, Yoshida S, Washiyama K, Kumanishi T: Immunohistochemical analysis of tumor-infiltrating lymphocytes and major histocompatibility antigens in human gliomas and metastatic brain rumors. Surg Neurol 29:435-442, 1988.
137. Sampson JH, Archer GE, Ashley DM, Fuchs HE, Hale LP, Dranoff G, Bigner DD: Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci U S A 93:10399-10404, 1996.
138. Sampson JH, Ashley DM, Archer GE, Fuchs HE, Dranoff G, Hale LP, Bigner DD: Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. Neurosurgery 41:1365-1372, 1997.
139. Sankhla SK, Nadkarni JS, Bhagwati SN: Adoptive immunotherapy using lymphokine-acrivated (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors. J Neurooncol 27:133-140, 1995.
140. Saris SC, Bigner SH, Bigner DD: Intracranial transplantation of a human glioma cell line in immunosuppressed rats. J Neurosurg 60:582-588, 1984.
141. Saris SC, Spiess P, Lieberman DM, Lin S, Walbridge S, Oldfield EH: Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes. J Neurosurg 76:513-519, 1992.
142. Sawamura Y, Diserens A-C, de Tribolet N: In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes. J Neurooncol 9:125-130, 1990.
143. Scheinberg LC, Edelman FL, Levy WA: Is the brain "an immunologically privileged site?": I - Studies based on intracerebral homotransplantation and isotransplantation to sensitized hosts. Arch Neurol 11:248-264, 1964.
144. Scheinberg LC, Kotsilimbas DG, Karpf R, Mayer N: Is the brain "an immunologically privileged site?": III - Studies based on homologous skin grafts to the brain and subcutaneous tissues. Arch Neurol 15:62-67, 1964.
145. Schoenberger SP, Toes REM, van der Voort EIH, Offringa R, Melief CJM: T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480-483, 1998.
146. Sheng WS, Hu S, Kravitz FH, Peterson PK, Chao CC: Tumor necrosis factor alpha upregulates human microglial cell production of interleukin-10 in vitro. Clin Diagn Lab Immunol 2:604-608, 1995.
147. Shevelev A, Burfeind P, Schulze E, Rininsland F, Johnson TR, Trojan J, Chernicky CL, Helene C, Ilan J, Ilan J: Potential triple helix-mediated inhibition of IGF-I gene expression significantly reduces tumorigenicity of glioblastoma in an animal model. Cancer Gene Ther 4:105-112, 1997.
148. Siepl C, Bodmer S, Frei K, MacDonald H, De Martin R, Hofer E, Fontana A: The glioblastoma derived T-cell suppressor factor/ transforming growth factor beta 2 inhibits T-cell growth without affecting the interaction of interleukin-2 with its receptor. Eur J Immunol 18:593-600, 1988.
149. Siesjo P, Visse E, Sjogren HO: Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment. J Immunother Tumor Immunol 19:334-345, 1996.
150. Sobol RE, Fakhrai H, Shawler D, Gjerset R, Dorigo O, Carson C, Khaleghi T, Koziol J, Shiftan TA, Royston I: Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther 2:164-167, 1995.
151. Tada M, de Tribolet N: Recent advances in immunobiology of brain tumors. J Neurooncol 17:261-271, 1993.
152. Tahara H, Lotze MT: Antitumor effects of interleukin-12 (IL-12): Applications for the immunotherapy and gene therapy of cancer. Gene Ther 2:96-106, 1995.
153. Theele DP, Streit WJ: A chronicle of microglial ontogeny. Glia 7:5-8, 1993.
154. Toda K, Shiraishi T, Hirotsu T, Fukuyama K, Mineta T, Kawaguchi S, Tabuchi K: The cytocidal activity of OD-432-activated mononuclear cells against human glioma cells is partly mediated through Fas ligand/Fas system. Jpn J Cancer Res 87:972-976, 1996.
155. Townsend SE, Allison JP: Tumour rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259:368-370, 1993.
156. Trojan J, Due HT, Upegui-Gonzalez LC, Hor F, Guo Y, Anthony D, Ilan J: Presence of MHC-I and B-7 molecules in rat and human glioma cells expressing antisense IGF-I mRNA. Neurosci Lett 212:9-12, 1996.
157. Trojan J, Johnson TR, Rudin SD, Ilan J, Tydocinski ML, Ilan J: Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I-RNA. Science 259:94-96, 1993.
158. Trouillas P: Immunology and immunotherapy of cerebral tumors: Current status [in French]. Rev Neurol (Paris) 128:23-38, 1973.
159. Tseng SH, Hwang LH, Lin SM: Induction of antitumor immunity by intracerebrally implanted rat C6 glioma cells genetically engineered to secrete cytokines. J Immunother 20:334-342, 1997.
160. Tsunawaki S, Sporn M, Ding A: Deactivation of macrophages by transforming growth factor beta. Nature 334:260-262, 1988 (letter).
161. Tzeng JJ, Earth RF, Clendenon NR, Gordon WA: Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin-2. Cancer Res 50:4338-4343, 1990.
162. Van Damme J, Wuyts A, Froyen G, Van Coillie E, Struyf S, Billiau A, Proost P, Wang JM, Opdenakker G: Granulocyte chemotactic protein-2 and related CXC chemokines: From gene regulation to receptor usage. J Leukocyte Biol 62:563-569, 1997.
163. Van Meir EG: Cytokines and tumors of the central nervous system. Glia 15:264-288, 1995.
164. Van Meir E, Ceska M, Effenberger F, Walz A, Grouzmann E, Desbaillets I, Frei K, Fontana A, de Tribolet N: Interleukin-8 is produced in neoplastic and infectious diseases of the human central nervous system. Cancer Res 52:4297-4305, 1992.
165. Van Meir E, Sawamura Y, Diserens A-C, Hamou M-F, de Tribolet N: Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res 50:6683-6688, 1990.
166. von Hanswehr RI, Hofman FM, Taylor CR, Apuzzo MLJ: Mononuclear lymphoid populations infiltrating the microenvironment of primary CNS tumors: Characterization of cell subsets with monoclonal antibodies. J Neurosurg 60:1138-1147, 1984.
167. von Wild KR, Knocke TH: The effects of local and systemic Interferon beta (Fiblaferon) on supratentorial malignant cerebral glioma: A phase II study. Neurosurg Rev 14:203-213, 1991.
168. Waldmann TA: The IL-2/IL-2 receptor system: A target for rational immune intervention. Immunol Today 14:264-270, 1993.
169. Walker PR, Saas P, Dietrich PY: Role of Fas ligand (CD95L) in immune escape: The tumor cell strikes back. J Immunol 158: 4521-4524, 1997.
170. Wallenfriedman MA, Conrad JA, DelaBarre L, Graupman PC, Lee G, Garwood M, Gregerson DS, Jean WC, Hall WA, Low WC: Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression. J Neurosurg 90:1064-1071, 1999.
171. Wei MX, Tamiya T, Hurford RKJ, Boviatsis EJ, Tepper RI, Chiocca EA: Enhancement of interleukin-4-mediated tumor regression in athymic mice by in situ retroviral gene transfer. Hum Gene Ther 6:437-443, 1995.
172. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A: Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. J Clin Invest 94:954-964, 1994.
173. Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A: Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 95:2633-2643, 1995.
174. Weller M, Malipiero U, Rensing-Ehl A, Barr PJ, Fontana A: Fas/APO-1 gene transfer for human malignant glioma. Cancer Res 55:2936-2944, 1995.
175. Wen PY, Lampson MA, Lampson LA: Effects of gamma interferon on MHC expression and lymphocytic infiltration in the 9L gliosarcoma brain tumor model: Implication for strategies of immunotherapy. J Neuroimmunol 36:57-68, 1992.
176. Westphal M, Hansel M, Brunken M, Konig A, Koppen JA, Herrman HD: Initiation of primary cell cultures from human intracranial tumors on extracellular matrix from bovine corneal endothelial cells. Exp Cell Biol 55:152-163, 1987.
177. Westphal M, Hansel M, Nausch H, Rohde E, Koppen J, Fiola M, Holzel F, Herrmann H-D: Glioma biology in vitro: Goals and concepts. Acta Neurochir Suppl (Wien) 43:107-113, 1988.
178. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ: Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55:3140-3148, 1995.
179. Wood GW, Morantz RA: Immunohistochemical evaluation of the lymphoreticular infiltrate of human central nervous system tumors. J Natl Cancer Inst 62:485-491, 1979.
180. Wu T-C, Huang A, Jaffee E, Levitsky H, Pardoll D: A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 182:1415-1421, 1995.
181. Yamada S, DePasquale M, Patlak CS, Cserr HF: Albumin out-flow into deep cervical lymph from different regions of rabbit brain. Am J Physiol 261:H1197-H1204, 1991.
182. Yoshida J, Wakabayashi T, Mizuno M, Sugita K, Yoshida T, Hori S, Mori T, Sato T, Karashima A, Kurisu K: Clinical effect of intra-arterial tumor necrosis factor-alpha for malignant glioma. J Neurosurg 77:78-83, 1992.
183. Young H, Kaplan A, Regelson W: Immunotherapy with autologous white cell infusions ("lymphocytes") in the treatment of recurrent glioblastoma multiforme. Cancer 40:1037-1044, 1977.
184. Young HF, Sakalas R, Kaplan AM: Inhibition of cell-mediated immunity in patients with brain tumors. Surg Neurol 5:19-23, 1976.
185. Yu JS, Burwick JA, Dranoff G, Breakefield XO: Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum Gene Ther 8:1065-1072, 1997.
186. Yu JS, Wei MX, Chiocca EA, Martuza RL, Tepper RI: Treatment of glioma by engineered interleukin-4 secreting cells. Cancer Res 53:3125-3128, 1993.
187. Yung WK, Prados M, Levin VA, Fetell MR, Bennett J, Mahaley MS, Salcman M, Etcubanas E: Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: A phase I/II study. J Clin Oncol 9:1945-1949, 1991.
188. Zielask J, Hartung H-P: Molecular mechanisms of microglial activation. Adv Neuroimmunol 6:191-222, 1996.
189. Zlokovic BV, Apuzzo MLJ: Cellular and molecular neurosurgery: Pathways from concept to reality - Part I: Target disorders and concept approaches to gene therapy of the central nervous system. Neurosurgery 40:789-804, 1997.
190. Zlokovic BV, Apuzzo MLJ: Cellular and molecular neurosurgery: Pathways from concept to reality - Part II: Vector systems and delivery methodologies for gene therapy of the central nervous system. Neurosurgery 40:805-813, 1997.